2023-505185-28-00
尚未招募
1 期
An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.
概览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 52
- 试验地点
- 11
概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（65+ Years, 18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Trial Information System - TISL
Scientific
F. Hoffmann-La Roche AG
研究点 (11)
Loading locations...
相似试验
已完成
1 期
A phase Ib study to investigate the safety and effect of BR-0032024-516338-37-00SentryX B.V.6
招募中
1 期
A Phase I trial to establish the safety and maximum tolerated dose of high-affinity autologous BCMA-targeting CAR-T cells in patients with relapsed and refractory B-cell malignancies (CARLOTTA01)2022-502831-20-00Technische Universitat Dresden16
招募中
1 期
Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors2022-502867-39-00Amgen Inc.58
招募中
1 期
A Phase 1 Study to Investigate the Safety and Tolerability of the Study Drug GB-0895 in Mild to Moderate Asthma Patients or Single Dose in Chronic Obstructive Pulmonary Disease (COPD)2023-507611-35-00Generate Biomedicines Inc.70
暂停
1 期
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of the DGKζ Inhibitor BGB-30813, Alone or in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab, in Patients With Advanced or Metastatic Solid Tumors2023-503996-38-00Beigene Ltd.60